856677-01-5

Basic information

• Product Name: (R)-5-(azidomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one
• Synonyms: (R)-5-(azidomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one
• CAS NO: 856677-01-5
• Molecular Weight: 315.102
• Mol File: 856677-01-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-5-(azidomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-5-(azidomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one(856677-01-5)
• EPA Substance Registry System: (R)-5-(azidomethyl)-3-(4-bromo-3-fluorophenyl)oxazolidin-2-one(856677-01-5)

Safety Data

• Hazardous Substances Data: 856677-01-5(Hazardous Substances Data)

Upstream product

• 856676-99-8 methanesulfonic acid (5R)-3-(4-bromo-3-fluorophenyl)-2-oxooxazolidin-5-ylmethyl ester 
• 656-65-5 3-fluoro-4-bromophenylamine 

Downstream Products

• 504437-66-5 (S)‐N‐((3‐(3‐fluoro‐4‐(4,4,5,5‐tetramethyl‐1,3,2‐dioxaborolan‐2‐yl)phenyl)‐2‐oxooxazolidin‐5‐yl)methyl)acetamide 
• 1401341-59-0 C₂₁H₂₁FN₆O₄ 
• 1401341-60-3 C₂₀H₂₁FN₆O₃*ClH 
• 1401341-61-4 C₂₁H₂₃FN₆O₃ 
• 1401341-63-6 C₂₄H₂₇FN₆O₅ 
• 1401341-64-7 C₂₂H₂₅FN₆O₄ 
• 1401341-65-8 C₂₃H₂₅FN₆O₃ 
• 1401341-66-9 C₂₃H₂₃FN₆O₃ 
• 1401341-67-0 C₂₆H₃₁FN₆O₅ 
• 1401341-69-2 C₂₂H₂₃FN₆O₅ 
• 1401341-70-5 C₂₄H₂₅FN₆O₆ 
• 1401341-71-6 C₂₆H₂₇FN₆O₈ 
• 1401341-72-7 C₃₆H₃₆FN₆O₈P 
• 1401341-74-9 C₂₂H₂₄FN₇O₄ 

Relevant articles and documents

OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS

The present invention relates to oxazolidinone compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosiscomprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or apharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME

Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.